texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician

Rene Castillo, M.D.

Education

  • Fellowship in Hematology/Medical Oncology
    Cornell Medical Center, New York, NY
  • Chief Fellow in Hematology/Medical Oncology
    Cornell Medical Center, New York, NY
  • Chief Resident in Internal Medicine
    St Luke's/Roosevelt Hospital Center, New York, NY
  • Internship & Residency in Internal Medicine
    St Luke's/Roosevelt Hospital Center, New York, NY
  • Rotating Internship
    Dr. Manuel Gea Gonzales General Hospital, Mexico City, MX
  • Medical Degree
    Universidad La Salle Medical School, Mexico City, MX

Accolades & Memberships

  • "Best Doctors in America," Best Doctors Database
  • "Top Doctors in New Orleans," New Orleans Magazine
  • Community of Caring Award, Ochner Clinic Foundation New Orleans, Louisiana
  • Texas Medical Association
  • Travis County Medical Society
  • American College of Physicians
  • American Medical Association
  • American Society of Clinical Oncology
  • American Society of Hematology
  • New York State Society of Internal Medicine
  • North Central Cancer Treatment Group
  • Eastern Cooperative Oncology Group
  • Radiation Treatment Oncology Group
  • National Surgical Adjuvant Breast & Bowel Project

Publications

  • Continued Late Conversion to Compete Remission (*CR/Cm) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by MitumprotiMut-T (Id-KLH, FavID®) Active Immunotherapy

    Blood, 2007

  • Active Immunotherapy with Mitumprotirnut-T (FavId®, Id-KLH) Following Rituxirnab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL); Progression Free Survival (PFS) at 4-Years Follow Up

    Blood, 2007

  • Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement and Disease Progression in Follicular Lymphoma Patients

    Blood, 2006

  • Should Elderly Non-Small Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group

    Journal of Clinical Oncology, 2005

  • Efficacy and Safety Analysis of Epoetin Alfa in Patients with Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

    Journal of Clinical Oncology, 2005

Show all Publications
  • Intravascular B-cell Lymphoma

    Community Oncology, 2005

  • Id/KLH Vaccine (Favidl) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRl) and Time-to-Progression (ITP) in Follicular Lymphoma (FL)

    Blood, 2004

  • Oral Vinorelbine for the Treatment of Metastatic Non-small Cell Lung Cancer in Elderly Patients: a Phase II Trial of Efficacy and Toxicity

    Lung Cancer, 2004

  • Effects of Early Intervention with Epoetin Alfa in Patients with Small Cell Lung Cancer (SCLC)

    Lung Cancer, 2003

  • Modulation of Mantle Cell Lymphoma Cell Growth by T-Cell Derived Stimuli

    Leukemia, 2003

  • Favld™ [Id-KLH Vaccine] Following Rituximab for Patient with Indolent NHL

    Journal of the American Society of Hematology, 2003

  • Validation of Neuroradiologic Response Assessment in Gliomas: RECIST (1D) vs 2D Measurements vs Computer-Assisted Tumor Area vs Volume

    ASCO 39th Annual Meeting, 2003

  • Oral Vinorelbine in Elderly Patients (≥65 years old) With Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase II Trial from the North Central Cancer Treatment Group

    ASCO 39th Annual Meeting, 2003

  • Phase I Study of Weekly Paclitaxel and Vinorelbine in Patients with Advanced Solid Tumors

    ASCO 39th Annual Meeting, 2003

  • Doppler Echocardiography: Clinical Overview

    Revista Medica La Salle, 1985

Research Interest

  • A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Drug A With and Without Drug B in the First-line Treatment of Subject With Metastatic Colorectal Cancer
  • Phase II, Multicenter, Open-Label, Non-Randomized Study of Intravenous Drug A Q 3 Weeks in Patients with Metastatic Breast Cancer Progressing After Therapy with Drug B, Drug C, and Drug D
  • A Phase III Trial of Novel Drug A Plus Drug B versus Drug B Alone in Patients with Advanced Breast Cancer Previously Treated with or Resistant to a Drug C and who are Drug D Resistant
  • Randomized Trial of Plus Chemotherapies in Metastatic Breast Cancer in 1st and 2nd Line Patients
  • A Randomized, Open-label Trial Comparing Drug A and Drug B Drug-based Treatment Regimens for the First-line Treatment of Metastatic Colorectal Cancer (mCRC)
  • A Phase III, Multicenter, Placebo-Controlled, Double-Blind, randomized Clinical Trial To Evaluate The Efficacy Of Drug A In Combination With Drug B Compared With Drug A Alone For Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure Of Standard First-Line Chemotherapy
  • Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Drug A 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Drug A Drug 0.25 mg IV for the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer.
  • A Phase IV Open Label Trial Using Drug A for Re-treatment of Multiple Myeloma Patients Following an Initial Response to Drug B
  • A Randomized Phase II Comparative Study of Drug A and Drug B Second-Line Therapy for Patients with Resistant and Refractory Small Cell Lung Cancer
  • A Dual-cohort, Perspective, Observational Study of Unresectable Stage IIIB/IV Non-small Cell Lung Cancer Patients with and without Bone Metastasis

Medical Practice

  • Physician, Hematology/Medical Oncology, Texas Oncology Central Austin, Austin, Texas (2008-Present)
  • Physician, Hematology/Medical Oncology, Southwest Regional Cancer Center, Austin, Texas (2006-2008)
  • Physician, Hematology/Medical Oncology, Ochsner Clinic Foundation, New Orleans, Louisiana (1998-2006)
  • Louisiana Blood Bank, New Orleans, Louisiana (1989-1991)
  • Social Services—Research, National Cancer Institute, Mexico City, MX (1987-1989)